Published in Bioorg Med Chem Lett on May 27, 2007
Neurological perspectives on voltage-gated sodium channels. Brain (2012) 1.62
Ion channels as drug targets: the next GPCRs. J Gen Physiol (2008) 1.51
Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain (2011) 1.32
Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol (2011) 1.16
AMPK: An emerging target for modification of injury-induced pain plasticity. Neurosci Lett (2013) 0.91
Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics (2009) 0.91
Contribution of primary afferent channels to neuropathic pain. Curr Pain Headache Rep (2009) 0.85
Na(+) channel blockers for the treatment of pain: context is everything, almost. Exp Neurol (2007) 0.85
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis. J Med Chem (2014) 0.75
The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development. PLoS One (2017) 0.75
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity (2009) 4.51
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A (2003) 3.17
Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2004) 2.80
Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology (2002) 2.64
Therapeutic potential of venom peptides. Nat Rev Drug Discov (2003) 2.39
Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol Biol Cell (2007) 2.28
ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell (2006) 2.26
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A (2002) 2.00
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells (2006) 1.91
Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A (2005) 1.84
Labeling proteins with small molecules by site-specific posttranslational modification. J Am Chem Soc (2004) 1.84
Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature (2003) 1.84
The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci (2002) 1.82
ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol (2008) 1.72
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 1.70
Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology (2010) 1.61
Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain (2005) 1.60
Reactive oxygen species impair Slo1 BK channel function by altering cysteine-mediated calcium sensing. Nat Struct Mol Biol (2004) 1.57
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia. J Med Chem (2012) 1.53
Ion channels as drug targets: the next GPCRs. J Gen Physiol (2008) 1.51
Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Res (2006) 1.51
Fluorescent saxitoxins for live cell imaging of single voltage-gated sodium ion channels beyond the optical diffraction limit. Chem Biol (2012) 1.50
Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry (2002) 1.48
Reduced opioid consumption and improved early rehabilitation with local and intraarticular cocktail analgesic injection in total hip arthroplasty: a randomized controlled clinical trial. Pain Med (2011) 1.47
The role of hypoxia-inducible factor-1α, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg (2010) 1.46
Estimating the number of low-income americans exposed to household air pollution from burning solid fuels. Environ Health Perspect (2014) 1.41
Up-regulation of tumor suppressor genes might promote the malignant phenotype of cancer cells. Med Hypotheses (2007) 1.39
A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A (2002) 1.38
Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res (2005) 1.36
Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion. Diabetes (2006) 1.35
Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc Natl Acad Sci U S A (2008) 1.35
Structural determinants for functional coupling between the beta and alpha subunits in the Ca2+-activated K+ (BK) channel. J Gen Physiol (2006) 1.33
Amiodarone pulmonary toxicity. Clin Chest Med (2004) 1.27
Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain (2005) 1.16
Expression of voltage-gated potassium channels in human and rhesus pancreatic islets. Diabetes (2004) 1.16
An improved western blotting technique effectively reduces background. Electrophoresis (2002) 1.16
Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem (2005) 1.16
BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem (2002) 1.16
Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem (2006) 1.15
Evaluation of postoperative analgesia in a rat model of incisional pain. Contemp Top Lab Anim Sci (2003) 1.14
Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther (2010) 1.14
Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain (2006) 1.13
Fasting enhances the response of arcuate neuropeptide Y-glucose-inhibited neurons to decreased extracellular glucose. Am J Physiol Cell Physiol (2009) 1.12
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res (2006) 1.08
5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal (2010) 1.06
Residual structure in the repeat domain of tau: echoes of microtubule binding and paired helical filament formation. Biochemistry (2005) 1.06
Nodulisporic acids D-F: structure, biological activities, and biogenetic relationships. J Nat Prod (2004) 1.06
Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: selectivity between voltage-gated and Maxi-K channels. Proteins (2003) 1.05
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. Eur J Pharmacol (2010) 1.05
Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer (2005) 1.05
Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry (2008) 1.04
In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol Aging (2005) 1.04
Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun (2006) 1.04
Implementation of evidence-based asthma interventions in post-Katrina New Orleans: the Head-off Environmental Asthma in Louisiana (HEAL) study. Environ Health Perspect (2012) 1.04
Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev Technol (2004) 1.03
Intramolecular Diels-Alder reactions of cycloalkenones: translation of high endo selectivity to trans junctions. J Am Chem Soc (2012) 1.03
The behavioral and neuroanatomical effects of IB4-saporin treatment in rat models of nociceptive and neuropathic pain. Brain Res (2004) 1.03
Regulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cells. Brain Res Mol Brain Res (2004) 1.03
Protein surface recognition by rational design: nanomolar ligands for potassium channels. J Am Chem Soc (2003) 1.02
A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol (2008) 1.02
Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J Biol Chem (2002) 1.02
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther (2007) 1.02
Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry (2007) 1.01